Skip to content

Massimo Guidoboni

University of Siena

1 paper in the Anchorcite directory, published in 2017, cited 5,446 times in total.

ORCID profile

Research topics

Frequent co-authors

Papers

  1. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced MelanomaNew England Journal of Medicine · 2017 · 5,446 citations

    BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma. We now report 3-year overall survival outcomes in this trial. METHODS:…

Metadata from OpenAlex (CC0).